PLYX — Polaryx Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 2075320 ·
Last close
$1.60
Market Cap
$75.75M
52W High
$48.91
52W Low
$1.58
ADV30
25,872
Next earnings
—
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -3,328,000 -3,328,000 8,610,000 8,440,000 999,000
Jun 2026 0 — -1,380,000 -1,380,000 11,812,000 11,542,000 873,000
Mar 2026 0 — -1,958,000 -2,544,000 3,502,000 3,080,000 1,014,000
Dec 2025 0 — -911,000 -1,495,000 5,170,000 5,143,000 605,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-5,809,000
Investing CF
—
Financing CF
$14,047,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.13
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-103,559,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-5,223,000
Pretax Income TTM
$-6,849,000
Interest Exp TTM
—
Analysts
4

Annual Trend (SEC EDGAR, last 3y)

Revenues vs Net Income (last 3y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -7,821,000 -8,985,000 5,170,000 605,000 4,565,000 -3,944,000
Dec 2024 0 -4,352,000 -30,356,000 5,001,000 289,000 4,712,000 -2,573,000
Dec 2023 0 -3,781,000 -3,779,000 2,315,000 1,038,000 1,277,000 -173,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$11,812,000
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
MAIA MAIA Biotechnology, Inc. $77.19M $1.25 —
RACC Research Alliance Corp III $78.68M $10.12 —
ZYBT Zhengye Biotechnology Holding Ltd $72.03M $1.52 —
COYA Coya Therapeutics, Inc. $70.84M $3.02 —
RLYB Rallybio Corp $82.32M $15.29 —

News headlines (Yahoo Finance, 1h cache)

Polaryx Therapeutics Activates First Clinical Trial Site for SOTERIA Phase 2 Basket Trial of PLX-200
2026-11-09 13:30 · Yahoo
Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer
2026-09-01 12:30 · Yahoo
Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial
2026-08-25 12:30 · Yahoo
Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference
2026-04-23 12:30 · Yahoo
Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial
2026-05-28 12:30 · Yahoo
Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care
2026-04-15 13:15 · Yahoo
Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards
2026-05-14 13:15 · Yahoo
Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial
2026-04-21 12:30 · Yahoo
Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference
2026-04-01 12:30 · Yahoo
Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)
2026-03-17 12:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.